Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Gynaecological cancer

Aurelia—ovarian combination

Nature Reviews Clinical Oncology volume 11, page 242 (2014)Cite this article

Subjects

Patients with platinum-resistant recurrent ovarian cancer have a poor prognosis. For these patients, single-agent chemotherapy is the standard of care, as chemotherapy drug combinations lead to increased toxicity with no additional benefit. However, the recently reported results of the AURELIA phase III open-label randomized trial indicate that combination of single-agent chemotherapy with bevacizumab should be considered a standard option for patients with platinum-resistant ovarian cancer.

The investigators enrolled 361 women with histologically confirmed ovarian cancer who had disease progression within 6 months of completing platinum-based therapy, and randomly assigned them to receive either standard chemotherapy alone or in combination with bevacizumab. Single-agent chemotherapy—which included either pegylated liposomal doxorubicin, topotecan, or weekly paclitaxel—was selected on an individual patient basis. The primary end point of the study was progression-free survival (PFS), and the secondary end points were objective response rate (ORR) and overall survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Puhiade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 10.1200/JCO.2013.51.4489

Download references

Authors
  1. Alessia Errico
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Errico, A. Aurelia—ovarian combination. Nat Rev Clin Oncol 11, 242 (2014). https://doi.org/10.1038/nrclinonc.2014.59

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.59

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing